RU98103388A - (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION - Google Patents

(R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION

Info

Publication number
RU98103388A
RU98103388A RU98103388/04A RU98103388A RU98103388A RU 98103388 A RU98103388 A RU 98103388A RU 98103388/04 A RU98103388/04 A RU 98103388/04A RU 98103388 A RU98103388 A RU 98103388A RU 98103388 A RU98103388 A RU 98103388A
Authority
RU
Russia
Prior art keywords
compound
formula
physiologically acceptable
acceptable acid
acid addition
Prior art date
Application number
RU98103388/04A
Other languages
Russian (ru)
Other versions
RU2156248C2 (en
Inventor
Като Сиро
Хирокава Есими
Морие Тосия
Харада Хироси
Есида Наоюки
Original Assignee
Дайниппон Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайниппон Фармасьютикал Ко., Лтд. filed Critical Дайниппон Фармасьютикал Ко., Лтд.
Publication of RU98103388A publication Critical patent/RU98103388A/en
Application granted granted Critical
Publication of RU2156248C2 publication Critical patent/RU2156248C2/en

Links

Claims (8)

1. Соединение (R)-5-бром-N-(1-этил-4-метилгексагидро-1Н-1,4-диазепин-6-ил)-2-метокси-6-метиламино-3-пиридинкарбоксамид, которое выражено приведенной ниже формулой I
Figure 00000001

или его физиологически приемлемые кислотно-аддитивные соли.1. The compound (R) -5-bromo-N- (1-ethyl-4-methyl-hexahydro-1H-1,4-diazepin-6-yl) -2-methoxy-6-methylamino-3-pyridine carboxamide, which is expressed as shown below formula I
Figure 00000001

or its physiologically acceptable acid addition salts. 2. Способ получения соединения по п.1, включающий реакцию соединения приведенной ниже формулы II
Figure 00000002

или его реакционноспособного производного с соединением приведенной ниже формулы III
Figure 00000003

и, если необходимо, превращение полученного продукта в форме свободного основания в соответствующую физиологически приемлемую кислотно-аддитивную соль.2. The method of obtaining the compounds according to claim 1, comprising the reaction of compounds of the following formula II
Figure 00000002

or a reactive derivative thereof with a compound of formula III below
Figure 00000003

and, if necessary, converting the resulting product in the free base form to the corresponding physiologically acceptable acid addition salt. 3. Лекарственный препарат, содержащий соединение формулы I по п.1 или его физиологически приемлемую кислотно-аддитивную соль. 3. A drug containing a compound of the formula I according to claim 1 or a physiologically acceptable acid addition salt thereof. 4. Антирвотный агент, содержащий соединение формулы I по п.1 или его физиологически приемлемую кислотно-аддитивную соль, в качестве активного ингредиента. 4. An anti-emetic agent containing a compound of formula I according to claim 1 or a physiologically acceptable acid addition salt thereof, as an active ingredient. 5. Фармацевтическая композиция, которая включает соединение формулы I по п. 1 или его физиологически приемлемую кислотно-аддитивную соль и носитель для медицинских препаратов. 5. A pharmaceutical composition which comprises a compound of the formula I according to claim 1 or a physiologically acceptable acid addition salt thereof and a carrier for medical preparations. 6. Способ лечения тошноты или рвоты, включающий введение пациенту, страдающему тошнотой или рвотой, эффективного количества соединения формулы I по п.1 или его физиологически приемлемой кислотно-аддитивной соли. 6. A method of treating nausea or vomiting, comprising administering to a patient suffering from nausea or vomiting, an effective amount of the compound of formula I according to claim 1 or a physiologically acceptable acid additive salt. 7. Применение соединения формулы I по п.1 или его физиологически приемлемой кислотно-аддитивной соли для лечения пациента, страдающего тошнотой или рвотой, или для профилактического лечения тошноты или рвоты. 7. The use of the compounds of formula I according to claim 1 or its physiologically acceptable acid additive salts for the treatment of a patient suffering from nausea or vomiting, or for the prophylactic treatment of nausea or vomiting. 8. Соединение (R)-6-амино-1-этил-4-метилгексагидро-1Н-1,4-диазепин, которое определяется нижеприведенной формулой III
Figure 00000004

или его кислотно-аддитивная соль.8. The compound (R) -6-amino-1-ethyl-4-methylhexahydro-1H-1,4-diazepine, which is defined by the following formula III
Figure 00000004

or its acid additive salt.
RU98103388/04A 1995-07-28 1996-07-23 (r)-5-bromo-n-ethyl-4-methylhexahydro-1h-1,4-diazepin-6- yl)-2-methoxy-6 methylamino-3-pyridinecarboxamide, method of preparation thereof, pharmaceutical composition and antiemetic agent comprising said compounds, and intermediate compound thereof RU2156248C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP07212495 1995-07-28
JP7/212495 1995-07-28

Publications (2)

Publication Number Publication Date
RU98103388A true RU98103388A (en) 1999-11-10
RU2156248C2 RU2156248C2 (en) 2000-09-20

Family

ID=16623612

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98103388/04A RU2156248C2 (en) 1995-07-28 1996-07-23 (r)-5-bromo-n-ethyl-4-methylhexahydro-1h-1,4-diazepin-6- yl)-2-methoxy-6 methylamino-3-pyridinecarboxamide, method of preparation thereof, pharmaceutical composition and antiemetic agent comprising said compounds, and intermediate compound thereof

Country Status (25)

Country Link
US (1) US5945415A (en)
EP (1) EP0855397B1 (en)
KR (1) KR19990028395A (en)
CN (1) CN1096459C (en)
AT (1) ATE201021T1 (en)
AU (1) AU700635B2 (en)
BR (1) BR9609691A (en)
CA (1) CA2228056A1 (en)
CZ (1) CZ290442B6 (en)
DE (1) DE69612753T2 (en)
DK (1) DK0855397T3 (en)
ES (1) ES2156616T3 (en)
GR (1) GR3036089T3 (en)
HK (1) HK1018049A1 (en)
HU (1) HUP9901208A3 (en)
IL (1) IL122753A (en)
MX (1) MX9800620A (en)
NO (1) NO312964B1 (en)
NZ (1) NZ312799A (en)
PL (1) PL184073B1 (en)
PT (1) PT855397E (en)
RU (1) RU2156248C2 (en)
SK (1) SK282044B6 (en)
TR (1) TR199800165T1 (en)
WO (1) WO1997005129A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650778C2 (en) * 1996-12-06 2001-01-04 Asta Medica Ag Use of dopamine receptor antagonists in palliative tumor therapy
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
ITBO20020198A1 (en) * 2002-04-12 2003-10-13 Univ Bologna DERIVATIVES 2, 5 BIS DIAMMINO 1, 4 BENZOCHENIONIC USEFUL FOR THE TREATMENT OF ALZHEIMER DISEASE, METHOD FOR THEIR PREPARATION AND
JP2006516977A (en) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド How to treat nausea, vomiting, retching, or any combination thereof
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
DE602004007225T2 (en) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham METHOD FOR THE TREATMENT OF LOWER HARN PATTERNS
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
AU2010231439A1 (en) 2009-03-31 2011-10-27 Zeria Pharmaceutical Co., Ltd. Method for manufacturing 1,5-benzodiazepine derivative
WO2012026529A1 (en) 2010-08-26 2012-03-01 興和株式会社 Novel production method for isoquinoline derivatives and salts thereof
CA2938387C (en) * 2014-02-03 2021-03-02 Mylan Laboratories Ltd Processes for the preparation of intermediates of raltegravir

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
US5166341A (en) * 1988-07-29 1992-11-24 Dainippon Pharmaceutical Co., Ltd. 6-amino-1,4-hexahydro-1H-diazepine derivatives
JPH03223265A (en) * 1990-01-26 1991-10-02 Dainippon Pharmaceut Co Ltd Cyclic diamine derivative
JPH04210970A (en) * 1990-01-26 1992-08-03 Dainippon Pharmaceut Co Ltd Benzamide derivative and its intermediate
PT100990A (en) * 1991-10-24 1994-01-31 Smithkline Beecham Plc PYRIDINE DERIVATIVES AND THEIR USE AS A THERAPEUTIC SUBSTANCE

Similar Documents

Publication Publication Date Title
NO974163D0 (en) Ester of 5-aminolevulinic acid as a photosensitizer in photochemotherapy
DE69939532D1 (en) GAMMA AMINOBUTTERIC ACID DERIVATIVES, SOLID MEDICAMENTS AND METHOD FOR THE PRODUCTION THEREOF
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
AU8268591A (en) Codeine salt of a substituted carboxylic acid, processes for the preparation thereof, its use and pharmaceutical compositions
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
TR200101163T2 (en) Bile water substituted phenyl-alkenoylguanidines, production methods, uses
BG60101B2 (en) Method for preparing of 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]thionil]-1h-benzimidazo le
DE69217613D1 (en) Bicyclic derivatives containing nitrogen, processes for their preparation and pharmaceutical preparations containing them
HU903092D0 (en) Process for the preparation of buten-carboxylic acid derivatives and pharmaceutical compositions containing such compounds
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
CA2373962A1 (en) Immediate release medicinal compositions for oral use
MY133438A (en) Morpholinobenzamide salts
HU9500175D0 (en) Pharmacologically active alpha-[tertiary-aminomethyl]-benzenemethanol derivatives
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
WO2001007029A3 (en) Substituted guanidines and the use thereof
JPS5942318A (en) Therapeutical composition, manufacture and use
IE43848L (en) Pharmaceutical compositions
KR910002789A (en) Acrylate, preparation method thereof, pharmaceutical composition containing the same and method of using the same in medicine
RU99108789A (en) INHIBITOR OF SUBEPITELIAL POGGENITS
RU2000110629A (en) TETRAHYDROFURAN-CONTAINING PHOSPHATES AND HYDROXYESTERS AS MEDICINES FOR THE APPROPRIATE ANTIFUNGER
RU97113692A (en) APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CEREBRAL DEGENERATIVE DISORDERS
RU94026088A (en) Method of treating shock and process for inhibiting production of tumor necrosis alpha factor
RU97113495A (en) APPLICATION OF 3,4-DIPHENYL CHROMANS FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF IDIOPATHIC OR PHYIOLOGICAL GYNECOMMOSTIA
RU94011231A (en) Triple substituted derivatives of cycloalkane and method of their preparation
RU92016559A (en) DIALCOXY-PYRIDINYLBENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION, METHOD FOR INHIBITING OR TREATMENT, METHOD FOR PRODUCING THEM, USE AND INTERMEDIATE COMPOUNDS